Text Size

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00556998
First received: November 9, 2007
Last updated: February 27, 2012
Last verified: February 2012
History of Changes
Results First Received: August 2, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Pharmacokinetics Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Pharmacokinetics
Intervention: Drug: Voriconazole

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Treatments Voriconazole intravenous (IV) loading dose (6 mg/kg) was administered in the morning and evening on Day 1, and the IV maintenance dose (4 mg/kg) was administered in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated). The oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Participant Flow for 2 periods

 Period 1:   Voriconazole Intravenous (IV)
    All Treatments  
STARTED     26  
Treated     26  
COMPLETED     21 [1]
NOT COMPLETED     5  
Adverse Event                 1  
unspecified                 4  
[1] One participant received 2 days of oral; then received IV again before discontinuing from study.

Period 2:   Voriconazole Oral
    All Treatments  
STARTED     22 [1]
COMPLETED     20  
NOT COMPLETED     2  
Adverse Event                 1  
Intolerant of oral treatment                 1  
[1] One participant received voriconazole 150 mg every 12 hours during oral phase.



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
All Treatments Voriconazole intravenous (IV) loading dose (6 mg/kg) was administered in the morning and evening on Day 1, and the IV maintenance dose (4 mg/kg) was administered in the morning and evening on Days 2 to 7 (up to Day 20 if clinically indicated). The oral maintenance dosing regimen (300 mg every 12 hours or 150 mg every 12 hours if subject weighed less than 40 kg) was administered following voriconazole IV and lasted 6.5 days (up to Day 30 if clinically indicated).

Baseline Measures
    All Treatments  
Number of Participants  
[units: participants]
 		  26  
Age, Customized  
[units: Years]
 		 
12     4  
13     10  
>13 to <17     12  
Gender, Customized  
[units: Participants]
 		 
Female     9  
Male     17  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration   [ Time Frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion ]
  Show Outcome Measure 1

2.  Primary:   Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration   [ Time Frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion ]
  Show Outcome Measure 2

3.  Primary:   Time to Reach Cmax (Tmax) Following IV Administration   [ Time Frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion ]
  Show Outcome Measure 3

4.  Primary:   AUC12,ss Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]
  Show Outcome Measure 4

5.  Primary:   Cmax,ss Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]
  Show Outcome Measure 5

6.  Primary:   Tmax Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) Predose, 1, 2, 4, 6, 8, and 12 hours postdose ]
  Show Outcome Measure 6

7.  Secondary:   AUC12 Following IV Loading Dose   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion ]
  Show Outcome Measure 7

8.  Secondary:   Tmax Following an IV Loading Dose   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion ]
  Show Outcome Measure 8

9.  Secondary:   Cmax Following an IV Loading Dose   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion ]
  Show Outcome Measure 9

10.  Secondary:   Minimum Observed Plasma Trough Concentration (Cmin)   [ Time Frame: Day 7 (up to Day 20) for IV; Day 7 (up to Day 30) for oral at predose ]
  Show Outcome Measure 10

11.  Secondary:   AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion ]
  Show Outcome Measure 11

12.  Secondary:   Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion ]
  Show Outcome Measure 12

13.  Secondary:   Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration   [ Time Frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion ]
  Show Outcome Measure 13

14.  Secondary:   AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration   [ Time Frame: On Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]
  Show Outcome Measure 14

15.  Secondary:   Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]
  Show Outcome Measure 15

16.  Secondary:   Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration   [ Time Frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose ]
  Show Outcome Measure 16

17.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Loading Dose.   [ Time Frame: Day 1 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

18.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Steady State   [ Time Frame: Day 7 of IV dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

19.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral Dose All Subjects   [ Time Frame: Day 7 Oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

20.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral 300mg   [ Time Frame: Day 7 oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

21.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Loading Dose   [ Time Frame: Day 1 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

22.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Steady State   [ Time Frame: Day 7 of Intravenous dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

23.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax Day 7 Oral All Participants   [ Time Frame: Day 7 of oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

24.  Other Pre-specified:   Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax 300 mg Oral Dose   [ Time Frame: Day 7 of oral dosing ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00556998     History of Changes
Other Study ID Numbers: A1501081
Study First Received: November 9, 2007
Results First Received: August 2, 2010
Last Updated: February 27, 2012
Health Authority: United States: Food and Drug Administration